Exploratory Validation of Sleep-Tracking Devices in Patients with Psychiatric Disorders.

"Disclosure Dr. Mishima has received speaker’s honoraria from EISAI Co, Ltd; Nobelpharma Co, Ltd; Takeda Pharmaceutical Co, Ltd; and MSD Inc and research grants from The Japan Agency for Medical Research and Development (AMED) (JP21dk0307103KM), grants from The Japanese Ministry of Education, Science, and Technology (22568378), grants from The National Center of Neurology and Psychiatry (2-1); Eisai Co, Ltd; Sumitomo Pharma Co, Ltd; and Takeda Pharmaceutical Co, Ltd. Dr. Ozaki has received research support or speakers’ honoraria from, or has served as a consultant to, Sumitomo Pharma Co, Ltd; Eisai Co, Ltd; Otsuka Pharmaceutical Co, Ltd; KAITEKI Mitsubishi Chemical Group Corporation; Mitsubishi Tanabe Pharma Corp; Shionogi & Co, Ltd; Eli Lilly KK; MOCHIDA PHARMACEUTICAL CO, LTD; DAIICHI SANKYO Co, Ltd; Nihon Medi-Physics Co, Ltd; Takeda Pharmaceutical Co, Ltd; Meiji-Seika Pharma Co, Ltd; Kyowa Co, Ltd; EA Pharma Co, Ltd; Viatris Inc; Kyowa Kirin Co, Ltd; MSD Inc; Janssen Pharmaceutical KK; and Nippon Boehringer Ingelheim Co, Ltd, outside the submitted work. Dr. Nakagome has received speaker’s honoraria from Otsuka Pharmaceutical Co, Ltd; Sumitomo Pharma Co, Ltd; Meiji-Seika Pharma Co, Ltd; Janssen Pharmaceutical KK; MOCHIDA PHARMACEUTICAL CO, LTD; Mitsubishi Tanabe Pharma Corp; Viatris Inc; and Eisai Co, Ltd. He has received payment for advising from Takeda Pharmaceutical Co, Ltd; Lundbeck Japan; Nippon Boehringer Ingelheim Co, Ltd; Sumitomo Pharma Co, Ltd; and Otsuka Pharmaceutical Co, Ltd. He has also received research grants from Otsuka Pharmaceutical Co, Ltd; Sumitomo Pharma Co, Ltd; and Janssen Pharmaceutical KK, outside the submitted work; and grants from AMED during the conduct of the study."

"This research was supported by research grants from AMED (JP21dk0307103KM), the Japanese Ministry of Education, Science, and Technology (22H02992), and the National Center of Neurology and Psychiatry (2-1)."